BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about appointment of Secretarial auditors
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved standalone and consolidated audited financial results for Q4 and FY ended March 31, 2025, with a clean (unmodified) opinion from statutory auditor M/s P. Murali & Co. On a standalone basis, FY25 revenue from operations fell to Rs 6,098.58 lakhs from Rs 7,019.60 lakhs in FY24, with net profit nearly flat at Rs 360.13 lakhs (vs Rs 365.04 lakhs); Q4 FY25 slipped into a net loss of Rs 117.85 lakhs. On a consolidated basis, however, the company swung back to a profit of Rs 250.70 lakhs for FY25 from a loss of Rs 238.68 lakhs in FY24. The board re-appointed M/s Siva Ramakrishna & Associates as internal auditors for FY26 and appointed M/s BVR & Associates Company Secretaries LLP as secretarial auditors for a five-year term (FY26–FY30), subject to shareholder approval. It also noted that the first pharmaceutical formulation plant at Jadcherla, Hyderabad, has completed machinery installation, with operational qualification and validation expected by end-June 2025 and a manufacturing test licence application already filed.
For shareholders, this is largely a routine governance and results update. The weak standalone Q4 loss and revenue dip are concerns, but the consolidated turnaround to profit and the secretarial auditor appointment suggest improving compliance posture. Near-term stock focus will be on the Jadcherla formulation plant becoming operational, which could be a growth trigger if it commissions on schedule.